Peptides for Sexual Health

3 research peptides are currently studied for sexual health. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide recognized for its role as a non-selective agonist of melanocortin receptors, specifically MC3R and MC4R. Unlike traditional therapies for erectile dysfunction that primarily enhance vascular blood flow, PT-141 operates through the central nervous system, targeting the brain's melanocortin pathways to enhance sexual arousal and desire. Research indicates that PT-141 is effective in both men and women, particularly in addressing hypoactive sexual desire disorder (HSDD) in women and improving erectile function in men. Clinical trials have demonstrated its efficacy, with the SELECT trial administering 2.4 mg weekly via subcutaneous injection, resulting in significant improvements in sexual desire. The safety profile is generally favorable, with common side effects including nausea and headache, but further studies are warranted to fully understand long-term effects and optimal dosing strategies.

Bremelanotide, a cyclic peptide consisting of seven amino acids, serves as an agonist at melanocortin receptors MC3R and MC4R. This peptide has garnered attention for its ability to increase sexual desire specifically in premenopausal women diagnosed with HSDD. Clinical evidence suggests that Bremelanotide not only enhances sexual desire but also alleviates the psychological distress associated with low sexual desire. In clinical trials, participants reported significant improvements in sexual desire and overall sexual satisfaction. The FDA approved Bremelanotide under the brand name Vyleesi, indicating its potential as a therapeutic option for women experiencing HSDD. While the safety profile appears acceptable, with side effects including nausea and injection site reactions, ongoing research is crucial to further elucidate its long-term safety and efficacy in diverse populations.

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that functions as a non-selective agonist of melanocortin receptors, spanning from MC1R to MC5R. Initially developed for its photoprotective properties to promote skin tanning without UV exposure, Melanotan II has also been linked to effects on sexual function, particularly through its action on MC3R and MC4R. While research has indicated its potential to enhance sexual desire and arousal, Melanotan II remains unapproved for human use globally, with regulatory agencies, including the FDA, issuing warnings against its use due to safety concerns. The peptide's safety profile is not well established, and its side effects can include nausea, flushing, and increased libido, which may not be suitable for all individuals. As such, while Melanotan II has garnered interest in sexual health research, its lack of regulatory approval and associated safety warnings limit its clinical applicability.